Enrollment of oral powder T-1101 OPC phase trial has completed in Taiwan
2019.10.01
T-1101, oral powder for constitution (OPC), from Taivex has completed the phase I trial in Oct, 2019. Total 21 patients have received T-1101 (Tosylate) OPC
Project
T-1301, a multi-targeted anti-cancer developmental drug candidate, is licensed from The National Health Research Institutes to Taivex Therapeutics Corp.
2019.04.08
Taivex Therapeutics Corp. (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1301 (formerly, DBPR216), a potential anti-cancer
A major milestone for cancer drug development in Taivex! T-1101 OPC initiates Phase I clinical study
2017.09.01
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate
T-1101 OPC approved by the TFDA to start Phase I clinical study
2017.01.20
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 IND application has been
First in the worldwide! Oral powder T-1101 approved by the US FDA to start Phase I clinical study
2016.09.30
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 Investigational New Drug Application
T-1201 (DBPR115) Technique transfer from National Health Research Institute (NHRI)
2016.08.15
Taivex Therapeutics Corporation (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1201 (formerly, DBPR115), a potential anti-cancer